Fadraciclib (CYC065) is an investigational anticancer drug that inhibits CDK2 and CDK9 to block cancer cell growth and promote apoptosis. The directory classifies it as a under development API with a synthetic source/manufacturing origin. Other names for this substance include Cyclin Dependent Kinase Inhibitor 2/5/9 CYC065. Its PubChem CID is 24983461.
Fadraciclib
| CAS No | 1070790-89-4 |
|---|---|
| Molecular Formula | C21H31N7O |
| Molecular Weight | 397.50 g/mol |
| Synonyms | (2R,3S)-3-[[6-[(4,6-dimethyl-3-pyridinyl)methylamino]-9-propan-2-ylpurin-2-yl]amino]pentan-2-ol |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Fadraciclib (CYC065) is an investigational anticancer drug that inhibits CDK2 and CDK9 to block cancer cell growth and promote apoptosis. The directory classifies it as a under development API with a synthetic source/manufacturing origin.
The listed CAS number is 1070790-89-4.
The listed molecular formula is C21H31N7O.
The listed molecular weight is 397.50 g/mol.
(2R,3S)-3-[[6-[(4,6-dimethyl-3-pyridinyl)methylamino]-9-propan-2-ylpurin-2-yl]amino]pentan-2-ol.
The source lists Cyclin Dependent Kinase Inhibitor 2/5/9 CYC065.